How does GLP-3 (Retatrutide-class)'s half-life affect dosing?

GLP-3 (Retatrutide-class) has a plasma half-life of ~6 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1x weekly subq dosing at Trial doses 1-12 mg weekly per dose explains the typical onset timeline for anabolic and recovery endpoints.

What is the standard dosing protocol for GLP-3 (Retatrutide-class)?

Conventional GLP-3 (Retatrutide-class) dosing is Trial doses 1-12 mg weekly 1x weekly subq via subq. For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How does GLP-3 (Retatrutide-class) compare to IGF-1 LR3 and Tesamorelin?

GLP-3 (Retatrutide-class) (Triple-incretin receptor agonist, ~6 days half-life, Trial doses 1-12 mg weekly typical dose) differs from peers in the comparison table above. The principal points of difference relative to IGF-1 LR3 and Tesamorelin are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

What should I look for in GLP-3 (Retatrutide-class) sourcing and quality?

Acceptable GLP-3 (Retatrutide-class) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~4800 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What does GLP-3 (Retatrutide-class) stack well with?

For body composition / training protocols, GLP-3 (Retatrutide-class) pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from GLP-3 (Retatrutide-class)'s primary mechanism (Single molecule activating GLP-1, GIP, and glucagon receptors), producing additive or synergistic effects rather than receptor competition.

How should GLP-3 (Retatrutide-class) be stored and reconstituted?

Lyophilised GLP-3 (Retatrutide-class) stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Home/ Compounds/ GLP-3 (Retatrutide-class)

GLP-3 (Retatrutide-class)

Body Composition

Body composition response to GLP-3 (Retatrutide-class) is proportional to training stimulus and nutritional input. The triple GLP-1/GIP/glucagon receptor agonist class — early Phase II data shows weight loss exceeding semaglutide and tirzepatide. The compound contributes to the anabolic substrate, recovery window, or structural-adaptation layer depending on where its primary pharmacology acts. For trained athletes, the typical 8-12 week GLP-3 (Retatrutide-class) cycle produces visible composition shifts at week 4-8 with the standard Trial doses 1-12 mg weekly 1x weekly subq dose.

Body Composition / Training Applications

Injury RecoveryRecoveryCardiovascular ConditioningEnduranceStrength

Key Takeaways

Body composition lens: response to GLP-3 (Retatrutide-class) is proportional to training stimulus and nutritional adequacy.
Mechanism: Single molecule activating GLP-1, GIP, and glucagon receptors.
Body composition dose: Trial doses 1-12 mg weekly 1x weekly subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Single molecule activating GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and stimulates insulin; GIP contributes to insulin sensitization and adipose lipolysis; glucagon-receptor activation contributes to energy expenditure increase. Net effect: appetite suppression + thermogenesis. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by GLP-3 (Retatrutide-class).

Recovery window and training frequency

The most reliably reported effect of GLP-3 (Retatrutide-class) in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Hyperplasia and structural adaptation

Where GLP-3 (Retatrutide-class) demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Anabolic substrate and protein synthesis

GLP-3 (Retatrutide-class)'s relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Body Composition / Training Applications

Body Recomposition

The body composition community converges on GLP-3 (Retatrutide-class) for body recomposition with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Recovery

Recovery responds to GLP-3 (Retatrutide-class) with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Tendon Repair

For tendon repair, GLP-3 (Retatrutide-class) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Hyperplasia

The body composition community converges on GLP-3 (Retatrutide-class) for hyperplasia with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	Trial doses 1-12 mg weekly	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	Trial doses 1-12 mg weekly	4–6 weeks initial cycle
Body Composition focus	SubQ	Trial doses 1-12 mg weekly	1x weekly SubQ
Maintenance phase	SubQ	Trial doses 1-12 mg weekly	Ongoing with periodic pauses

Dose timing for GLP-3 (Retatrutide-class) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GLP-3 (Retatrutide-class) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

GLP-3 (Retatrutide-class) + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in body composition / training protocols.
GLP-3 (Retatrutide-class) + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in body composition / training protocols.
GLP-3 (Retatrutide-class) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in body composition / training protocols.
GLP-3 (Retatrutide-class) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Investigational (Phase III for obesity) Research: Phase II completed; Phase III enrolling

GI events similar to semaglutide. Heart rate elevation observed. Long-term safety pending.

Lens-specific safety considerations for body composition / training use of GLP-3 (Retatrutide-class): GI events similar to semaglutide. Heart rate elevation observed. Long-term safety pending. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Retatrutide triple receptor agonist Phase II in obesity

PMID 37364065

Supporting

Retatrutide in type 2 diabetes Phase II

PMID 37272677

GLP-3 (Retatrutide-class) vs Related Peptides

Compound	Profile	Onset	Best For
GLP-3 (Retatrutide-class)	Triple-incretin receptor agonist	~6 days	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Should I cycle GLP-3 (Retatrutide-class)?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

Best stack pairing for lean mass?

The canonical lean mass stack pairs GLP-3 (Retatrutide-class) with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Is GLP-3 (Retatrutide-class) safe during pregnancy or breastfeeding?

GLP-3 (Retatrutide-class), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the mechanism of action of GLP-3 (Retatrutide-class)?

Single molecule activating GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and stimulates insulin; GIP contributes to insulin sensitization and adipose lipolysis; glucagon-receptor activation contributes to energy expenditure increase. Net effect: appetite suppression + thermogenesis. For anabolic and recovery applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Single molecule activating GLP-1, GIP, and glucagon receptors. The body composition / training interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Clinical Protocol

Start a GLP-3 (Retatrutide-class) Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified GLP-3 (Retatrutide-class) and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: ~4800 Da
Half-life: ~6 days
WADA: Not on prohibited list
FDA: Investigational (Phase III for obesity)
Research: Phase II completed; Phase III enrolling

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GLP-3 (Retatrutide-class) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for GLP-3 (Retatrutide-class)

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised